SCHEMBL1663963

SCHEMBL1663963

O=c1c2ccc(O)cc2nc(C(C(F)(F)F)C(F)(F)F)n1-c1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.53
ESR1 P03372 3/20 0.50
ESR2 Q92731 3/20 0.43
MIF P14174 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
KDM4E B2RXH2 2/20 0.38
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
CYP2D6 P10635 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1663790 0.86 TRPV1 (0.49) TRPV1ESR1ESR2MIFSMN1; SMN2
SCHEMBL1663398 0.84 TRPV1 (0.72) TRPV1ESR1ESR2MIFSMN1; SMN2
SCHEMBL1665830 0.83 TRPV1 (0.61) TRPV1ESR1ESR2MIFSMN1; SMN2
SCHEMBL1666292 0.82 TRPV1 (0.60) TRPV1ESR1ESR2MIFSMN1; SMN2
SCHEMBL10445951 0.80 TRPV1 (0.57) TRPV1ESR1ESR2MIFSMN1; SMN2
SCHEMBL10446402 0.80 TRPV1 (0.57) TRPV1ESR1ESR2MIFSMN1; SMN2
SCHEMBL1663630 0.77 ESR1 (0.57) TRPV1ESR1ESR2MIFSMN1; SMN2
SCHEMBL1663648 0.77 ESR1 (0.53) TRPV1ESR1ESR2MIFSMN1; SMN2
SCHEMBL10445948 0.76 TRPV1 (0.68) TRPV1ESR1ESR2CXCR3
SCHEMBL1664004 0.76 ESR1 (0.84) TRPV1ESR1MIFSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305652-A2 Trisubstituted quinazolinone derivatives as vanilloid antagonists Novartis AG (CH) 2011-04-06 EP disclosed
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2009-03-26 US disclosed
EP-1963283-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007065662-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists TRPV1, TRPV3, TRPV5 TRPV1 1/4885ESR1 1321/4885ESR2 2159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.